| Jose Jeffrey Turtal Reasol, MD | |
|
10452 Silverdale Way Nw, Silverdale, WA 98383-9411 | |
| (360) 307-7300 | |
| (360) 307-7336 |
| Full Name | Jose Jeffrey Turtal Reasol |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 26 Years |
| Location | 10452 Silverdale Way Nw, Silverdale, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033152855 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD00045360 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harrison Medical Center | Bremerton, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
The deployment of soldiers to the ongoing conflicts in Iraq and Afghanistan is increasing the need for mental health services provided for their family members, according to a new study by researchers at RTI International, the University of North Carolina at Chapel Hill and the Uniformed Services University of the Health Sciences.
A new biomarker has identified known and unknown exposure to second-hand smoke and confirmed a strong association to increased mortality in non-smokers, according to a new study from the Icahn School of Medicine at Mount Sinai.
Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.
Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 9 days ago
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
The deployment of soldiers to the ongoing conflicts in Iraq and Afghanistan is increasing the need for mental health services provided for their family members, according to a new study by researchers at RTI International, the University of North Carolina at Chapel Hill and the Uniformed Services University of the Health Sciences.
A new biomarker has identified known and unknown exposure to second-hand smoke and confirmed a strong association to increased mortality in non-smokers, according to a new study from the Icahn School of Medicine at Mount Sinai.
Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.
Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 9 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
The deployment of soldiers to the ongoing conflicts in Iraq and Afghanistan is increasing the need for mental health services provided for their family members, according to a new study by researchers at RTI International, the University of North Carolina at Chapel Hill and the Uniformed Services University of the Health Sciences.
A new biomarker has identified known and unknown exposure to second-hand smoke and confirmed a strong association to increased mortality in non-smokers, according to a new study from the Icahn School of Medicine at Mount Sinai.
Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.
Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
The deployment of soldiers to the ongoing conflicts in Iraq and Afghanistan is increasing the need for mental health services provided for their family members, according to a new study by researchers at RTI International, the University of North Carolina at Chapel Hill and the Uniformed Services University of the Health Sciences.
A new biomarker has identified known and unknown exposure to second-hand smoke and confirmed a strong association to increased mortality in non-smokers, according to a new study from the Icahn School of Medicine at Mount Sinai.
Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.
Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 9 days ago
| Entity Name | Rockwood Clinic Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417953787 PECOS PAC ID: 8527976513 Enrollment ID: O20031117000912 |
News Archive
The deployment of soldiers to the ongoing conflicts in Iraq and Afghanistan is increasing the need for mental health services provided for their family members, according to a new study by researchers at RTI International, the University of North Carolina at Chapel Hill and the Uniformed Services University of the Health Sciences.
A new biomarker has identified known and unknown exposure to second-hand smoke and confirmed a strong association to increased mortality in non-smokers, according to a new study from the Icahn School of Medicine at Mount Sinai.
Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.
Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 9 days ago
| Entity Name | Fhs Inpatient Team |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326058017 PECOS PAC ID: 7012813421 Enrollment ID: O20031208000806 |
News Archive
The deployment of soldiers to the ongoing conflicts in Iraq and Afghanistan is increasing the need for mental health services provided for their family members, according to a new study by researchers at RTI International, the University of North Carolina at Chapel Hill and the Uniformed Services University of the Health Sciences.
A new biomarker has identified known and unknown exposure to second-hand smoke and confirmed a strong association to increased mortality in non-smokers, according to a new study from the Icahn School of Medicine at Mount Sinai.
Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.
Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jose Jeffrey Turtal Reasol, MD 10452 Silverdale Nw, Silverdale, WA 98383 Ph: (360) 307-7300 | Jose Jeffrey Turtal Reasol, MD 10452 Silverdale Way Nw, Silverdale, WA 98383-9411 Ph: (360) 307-7300 |
News Archive
The deployment of soldiers to the ongoing conflicts in Iraq and Afghanistan is increasing the need for mental health services provided for their family members, according to a new study by researchers at RTI International, the University of North Carolina at Chapel Hill and the Uniformed Services University of the Health Sciences.
A new biomarker has identified known and unknown exposure to second-hand smoke and confirmed a strong association to increased mortality in non-smokers, according to a new study from the Icahn School of Medicine at Mount Sinai.
Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.
Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 9 days ago
Tetyana Mcilvaine, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 9177 Ridgetop Blvd Nw, Silverdale, WA 98383 Phone: 360-307-6961 | |
Dr. Melike Arslan, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1950 Nw Myhre Rd, Fl 3, Silverdale, WA 98383 Phone: 564-240-4200 Fax: 564-240-4299 | |
Snehal R. Bansod, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1950 Nw Myhre Rd Fl 2, Silverdale, WA 98383 Phone: 564-240-4080 Fax: 564-240-4088 | |
Dmitry Tsimberov, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10452 Silverdale Way Nw, Silverdale, WA 98383 Phone: 360-307-7300 | |
Dr. William Michael Hall, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2011 Nw Myhre Pl, Silverdale, WA 98383 Phone: 360-830-1600 | |
Sujeen Adhikari, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1950 Nw Myhre Rd Fl 3, Silverdale, WA 98383 Phone: 564-240-4200 Fax: 564-240-4299 |